+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07007312

Phase 3 Studies Evaluating Ziftomenib With Standard Nonintensive or Intensive Therapy for Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia

Led by Kura Oncology, Inc. · Updated on 2026-10-13

1300

Participants Needed

136

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating ziftomenib, a drug targeting the menin pathway, for treating adults with acute myeloid leukemia AML who have specific genetic mutations. This research involves two parallel phase 3 studies comparing ziftomenib combined with standard therapies against placebo plus standard therapies in patients who have not yet received AML treatment. The studies focus on patients with nucleophosmin 1 mutation NPM1-m or lysine-specific methyltransferase 2A rearranged KMT2A-r AML. In the Nonintensive Therapy Study, older or medically unfit patients receive either ziftomenib or placebo alongside venetoclax and azacitidine. In the Intensive Therapy Study, medically fit patients are randomized to receive ziftomenib or placebo combined with cytarabine and daunorubicin during induction, cytarabine plus ziftomenib or placebo during consolidation, and ziftomenib or placebo alone during maintenance. Both studies use a double-blind design where neither patients nor physicians know the treatment assignments. Participants will be monitored for up to 36 months after enrollment, with evaluations including overall survival, event-free survival, complete remission rates, and measurable residual disease in bone marrow. Safety and tolerability will be assessed through adverse event reports and drug concentration measurements. Patient-reported outcomes related to health will also be collected. The total study duration extends up to November 2031, allowing long-term follow-up and assessment of treatment effects.

CONDITIONS

Brief Title

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Research Team

K

Kura Medical Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here